药明生物(02269.HK)与OncoC4建立独家CDMO合作夥伴关系
药明生物(02269.HK)宣布,与临床阶段生物制药公司OncoC4就其全部研发管线建立独家CDMO合作夥伴关系。OncoC4的研发管线包括新一代CTLA-4抗体ONC-392,目前该抗体正在美国和中国进行I期临床试验。
根据协议,药明生物将作为独家CDMO合作夥伴提供一体化研发和生产服务,满足OncoC4的生物药从早期研究、临床前至商业化阶段的需求。OncoC4将充分利用药明生物在细胞株、制剂等工艺开发,以及生物药原液和制剂生产领域的技术能力和经验,加速产品开发进程。
OncoC4并将进一步与药明生物扩大合作至双特异性抗体领域。根据协议,OncoC4获得授权使用WuXiBody技术平台发现和开发双抗药物;除首付款外,药明生物还将获得WuXiBody平台双抗药物的开发和商业化里程碑付款,以及产品上市後的净销售提成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.